Mesenchymal stromal cells and kidney transplantation: Pretransplant infusion protects from graft dysfunction while fostering immunoregulation

Norberto Perico, Federica Casiraghi, Eliana Gotti, Martino Introna, Marta Todeschini, Regiane Aparecida Cavinato, Chiara Capelli, Alessandro Rambaldi, Paola Cassis, Paola Rizzo, Monica Cortinovis, Marina Noris, Giuseppe Remuzzi

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Bone marrow-derived mesenchymal stromal cells (MSC) have emerged as useful cell population for immunomodulation therapy in transplantation. Moving this concept towards clinical application, however, should be critically assessed by a tailor-made step-wise approach. Here, we report results of the second step of the multistep MSC-based clinical protocol in kidney transplantation. We examined in two living-related kidney transplant recipients whether: (i) pre-transplant (DAY-1) infusion of autologous MSC protected from the development of acute graft dysfunction previously reported in patients given MSC post-transplant, (ii) avoiding basiliximab in the induction regimen improved the MSC-induced Treg expansion previously reported with therapy including this anti-CD25-antibody. In patient 3, MSC treatment was uneventful and graft function remained normal during 1 year follow-up. In patient 4, acute cellular rejection occurred 2 weeks post-transplant. Both patients had excellent graft function at the last observation. Circulating memory CD8+ T cells and donor-specific CD8+ T-cell cytolytic response were reduced in MSC-treated patients, not in transplant controls not given MSC. CD4+FoxP3+Treg expansion was comparable in MSC-treated patients with or without basiliximab induction. Thus, pre-transplant MSC no longer negatively affect kidney graft at least to the point of impairing graft function, and maintained MSC-immunomodulatory properties. Induction therapy without basiliximab does not offer any advantage on CD4+FoxP3+Treg expansion (ClinicalTrials.gov number: NCT 00752479).

Original languageEnglish
Pages (from-to)867-878
Number of pages12
JournalTransplant International
Volume26
Issue number9
DOIs
Publication statusPublished - Sep 2013

Fingerprint

Foster Home Care
Cell Transplantation
Mesenchymal Stromal Cells
Kidney Transplantation
Transplants
T-Lymphocytes
Kidney
Immunomodulation
Therapeutics
Clinical Protocols
Anti-Idiotypic Antibodies
Transplantation
Bone Marrow
Observation
Tissue Donors

Keywords

  • immunomodulation
  • living-related kidney transplantation
  • mesenchymal stromal cells
  • pretransplant cell infusion

ASJC Scopus subject areas

  • Transplantation

Cite this

Mesenchymal stromal cells and kidney transplantation : Pretransplant infusion protects from graft dysfunction while fostering immunoregulation. / Perico, Norberto; Casiraghi, Federica; Gotti, Eliana; Introna, Martino; Todeschini, Marta; Cavinato, Regiane Aparecida; Capelli, Chiara; Rambaldi, Alessandro; Cassis, Paola; Rizzo, Paola; Cortinovis, Monica; Noris, Marina; Remuzzi, Giuseppe.

In: Transplant International, Vol. 26, No. 9, 09.2013, p. 867-878.

Research output: Contribution to journalArticle

Perico, Norberto ; Casiraghi, Federica ; Gotti, Eliana ; Introna, Martino ; Todeschini, Marta ; Cavinato, Regiane Aparecida ; Capelli, Chiara ; Rambaldi, Alessandro ; Cassis, Paola ; Rizzo, Paola ; Cortinovis, Monica ; Noris, Marina ; Remuzzi, Giuseppe. / Mesenchymal stromal cells and kidney transplantation : Pretransplant infusion protects from graft dysfunction while fostering immunoregulation. In: Transplant International. 2013 ; Vol. 26, No. 9. pp. 867-878.
@article{137ebc72f1fc4c33a55011d8b20ae029,
title = "Mesenchymal stromal cells and kidney transplantation: Pretransplant infusion protects from graft dysfunction while fostering immunoregulation",
abstract = "Bone marrow-derived mesenchymal stromal cells (MSC) have emerged as useful cell population for immunomodulation therapy in transplantation. Moving this concept towards clinical application, however, should be critically assessed by a tailor-made step-wise approach. Here, we report results of the second step of the multistep MSC-based clinical protocol in kidney transplantation. We examined in two living-related kidney transplant recipients whether: (i) pre-transplant (DAY-1) infusion of autologous MSC protected from the development of acute graft dysfunction previously reported in patients given MSC post-transplant, (ii) avoiding basiliximab in the induction regimen improved the MSC-induced Treg expansion previously reported with therapy including this anti-CD25-antibody. In patient 3, MSC treatment was uneventful and graft function remained normal during 1 year follow-up. In patient 4, acute cellular rejection occurred 2 weeks post-transplant. Both patients had excellent graft function at the last observation. Circulating memory CD8+ T cells and donor-specific CD8+ T-cell cytolytic response were reduced in MSC-treated patients, not in transplant controls not given MSC. CD4+FoxP3+Treg expansion was comparable in MSC-treated patients with or without basiliximab induction. Thus, pre-transplant MSC no longer negatively affect kidney graft at least to the point of impairing graft function, and maintained MSC-immunomodulatory properties. Induction therapy without basiliximab does not offer any advantage on CD4+FoxP3+Treg expansion (ClinicalTrials.gov number: NCT 00752479).",
keywords = "immunomodulation, living-related kidney transplantation, mesenchymal stromal cells, pretransplant cell infusion",
author = "Norberto Perico and Federica Casiraghi and Eliana Gotti and Martino Introna and Marta Todeschini and Cavinato, {Regiane Aparecida} and Chiara Capelli and Alessandro Rambaldi and Paola Cassis and Paola Rizzo and Monica Cortinovis and Marina Noris and Giuseppe Remuzzi",
year = "2013",
month = "9",
doi = "10.1111/tri.12132",
language = "English",
volume = "26",
pages = "867--878",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Blackwell Publishing Ltd",
number = "9",

}

TY - JOUR

T1 - Mesenchymal stromal cells and kidney transplantation

T2 - Pretransplant infusion protects from graft dysfunction while fostering immunoregulation

AU - Perico, Norberto

AU - Casiraghi, Federica

AU - Gotti, Eliana

AU - Introna, Martino

AU - Todeschini, Marta

AU - Cavinato, Regiane Aparecida

AU - Capelli, Chiara

AU - Rambaldi, Alessandro

AU - Cassis, Paola

AU - Rizzo, Paola

AU - Cortinovis, Monica

AU - Noris, Marina

AU - Remuzzi, Giuseppe

PY - 2013/9

Y1 - 2013/9

N2 - Bone marrow-derived mesenchymal stromal cells (MSC) have emerged as useful cell population for immunomodulation therapy in transplantation. Moving this concept towards clinical application, however, should be critically assessed by a tailor-made step-wise approach. Here, we report results of the second step of the multistep MSC-based clinical protocol in kidney transplantation. We examined in two living-related kidney transplant recipients whether: (i) pre-transplant (DAY-1) infusion of autologous MSC protected from the development of acute graft dysfunction previously reported in patients given MSC post-transplant, (ii) avoiding basiliximab in the induction regimen improved the MSC-induced Treg expansion previously reported with therapy including this anti-CD25-antibody. In patient 3, MSC treatment was uneventful and graft function remained normal during 1 year follow-up. In patient 4, acute cellular rejection occurred 2 weeks post-transplant. Both patients had excellent graft function at the last observation. Circulating memory CD8+ T cells and donor-specific CD8+ T-cell cytolytic response were reduced in MSC-treated patients, not in transplant controls not given MSC. CD4+FoxP3+Treg expansion was comparable in MSC-treated patients with or without basiliximab induction. Thus, pre-transplant MSC no longer negatively affect kidney graft at least to the point of impairing graft function, and maintained MSC-immunomodulatory properties. Induction therapy without basiliximab does not offer any advantage on CD4+FoxP3+Treg expansion (ClinicalTrials.gov number: NCT 00752479).

AB - Bone marrow-derived mesenchymal stromal cells (MSC) have emerged as useful cell population for immunomodulation therapy in transplantation. Moving this concept towards clinical application, however, should be critically assessed by a tailor-made step-wise approach. Here, we report results of the second step of the multistep MSC-based clinical protocol in kidney transplantation. We examined in two living-related kidney transplant recipients whether: (i) pre-transplant (DAY-1) infusion of autologous MSC protected from the development of acute graft dysfunction previously reported in patients given MSC post-transplant, (ii) avoiding basiliximab in the induction regimen improved the MSC-induced Treg expansion previously reported with therapy including this anti-CD25-antibody. In patient 3, MSC treatment was uneventful and graft function remained normal during 1 year follow-up. In patient 4, acute cellular rejection occurred 2 weeks post-transplant. Both patients had excellent graft function at the last observation. Circulating memory CD8+ T cells and donor-specific CD8+ T-cell cytolytic response were reduced in MSC-treated patients, not in transplant controls not given MSC. CD4+FoxP3+Treg expansion was comparable in MSC-treated patients with or without basiliximab induction. Thus, pre-transplant MSC no longer negatively affect kidney graft at least to the point of impairing graft function, and maintained MSC-immunomodulatory properties. Induction therapy without basiliximab does not offer any advantage on CD4+FoxP3+Treg expansion (ClinicalTrials.gov number: NCT 00752479).

KW - immunomodulation

KW - living-related kidney transplantation

KW - mesenchymal stromal cells

KW - pretransplant cell infusion

UR - http://www.scopus.com/inward/record.url?scp=84882450956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882450956&partnerID=8YFLogxK

U2 - 10.1111/tri.12132

DO - 10.1111/tri.12132

M3 - Article

C2 - 23738760

AN - SCOPUS:84882450956

VL - 26

SP - 867

EP - 878

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 9

ER -